{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:47:20Z","timestamp":1790912840311,"version":"4.1.0"},"reference-count":92,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2016,7,2]]},"DOI":"10.1080\/17460441.2016.1187597","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T04:43:02Z","timestamp":1463028182000},"page":"665-680","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":56,"title":["Hybrid antibiotics \u2013 clinical progress and novel designs"],"prefix":"10.1080","volume":"11","author":[{"given":"Alastair L.","family":"Parkes","sequence":"first","affiliation":[{"name":",","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Yule","sequence":"additional","affiliation":[{"name":",","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,5,31]]},"reference":[{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0966-842X(96)30028-0"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1715163513486864"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.2307\/3755196"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00466-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00105"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00473-0"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e32833f0d3e"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2010.507193"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3975"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.07.005"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp255"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/emph\/eov025"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00030-10"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02045-12"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874285801307010034"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.06.007"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2012.12.006"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00749-14"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2007.09.004"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05041-11"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05685"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800944105"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2133"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2010.508069"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.01.060"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-7743(08)00017-1"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1070\/RCR4448"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02045-12"},{"key":"e_1_3_4_33_1","unstructured":"Actelion Pharmaceuticals. Clinical study to compare the efficacy and safety of Cadazolid versus Vancomycin in subjects with clostridium difficile-associated diarrhea. Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM identifier: NCT01987895. [cited 2016 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01987895"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026613666131113154753"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm5016846"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02045-12"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt401"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00504-15"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv300"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg486"},{"key":"e_1_3_4_41_1","unstructured":"Actelion Pharmaceuticals. Study to investigate the pharmacokinetics and safety of Cadazolid in patients with clostridium difficile infection. Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM identifier: NCT02053181. [cited 2016 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT02053181"},{"key":"e_1_3_4_42_1","unstructured":"Actelion Pharmaceuticals. ACT-179811 in patients with clostridium difficile infection. Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM identifier: NCT01222702. [cited 2016 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01222702"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06446-11"},{"key":"e_1_3_4_44_1","unstructured":"Theravance Biopharma Antibiotics Inc. TD-1792 in Gram-positive complicated skin and skin structure infection. Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM identifier: NCT00442832. [cited 2016 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT00442832"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06446-11"},{"key":"e_1_3_4_46_1","unstructured":"Infectious disease programs Theravance Biopharma website. 2016. [cited 2016 Jan 17]. Available from: http:\/\/www.theravance.com\/bacterial"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06446-11"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06446-11"},{"key":"e_1_3_4_49_1","volume-title":"Poster: Antimicrobial activity of TD-1607 tested against contemporary (2010-2012) methicillin-resistant staphylococcus aureus (MRSA) strains","author":"Sader HS","year":"2014","unstructured":"Sader HS, Rhomberg PR, Farrell DJ, et al. Poster: Antimicrobial activity of TD-1607 tested against contemporary (2010-2012) methicillin-resistant staphylococcus aureus (MRSA) strains. Washington (DC): ICAAC; 2014."},{"key":"e_1_3_4_50_1","unstructured":"Theravance Biopharma Antibiotics Inc. TD-1607 SAD study in healthy subjects. Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM identifier: NCT01791049. [cited 2016 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01791049"},{"key":"e_1_3_4_51_1","unstructured":"Theravance Biopharma Antibiotics Inc. TD-1607 MAD study in healthy subjects. Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. NLM identifier: NCT01949103. [cited 2016 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01949103"},{"key":"e_1_3_4_52_1","volume-title":"Poster: In vitro studies of the efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in killing staphylococcal cells in biofilms","author":"Doyle TB","year":"2007","unstructured":"Doyle TB, Bonventre EJ, Du Q, et al. Poster: In vitro studies of the efficacy of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic, in killing staphylococcal cells in biofilms. Chicago (ILL): ICAAC; 2007."},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01649-07"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr030112j"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01651-07"},{"key":"e_1_3_4_56_1","unstructured":"Cumbre announcement on completion of Phase I for CBR-2092. 2007. [cited 2016 Feb 14]. Available from: http:\/\/www.prnewswire.com\/news-releases\/cumbre-announces-new-financing-58476467.html"},{"key":"e_1_3_4_57_1","unstructured":"R & D Tenor Therapeutics website. 2016. [cited 2016 Feb 14]. Available from: http:\/\/www.tennorx.com"},{"key":"e_1_3_4_58_1","volume-title":"Poster: low propensity for development of resistance to MCB3681, the active moiety of oxaquin (MCB3837), in gram-positive bacteria with vancomycin-, linezolid-, methicillin- and\/or ciprofloxacin resistances","author":"Schubert S","year":"2006","unstructured":"Schubert S, Dalhoff A. Poster: low propensity for development of resistance to MCB3681, the active moiety of oxaquin (MCB3837), in gram-positive bacteria with vancomycin-, linezolid-, methicillin- and\/or ciprofloxacin resistances. San Francisco (CA): ICAAC; 2006."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2014.07.001"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.03.016"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.05.025"},{"key":"e_1_3_4_62_1","unstructured":"MCB3681 novel hybrid antibacterial Morphochem AG website. 2016. [cited 2016 Feb 14]. Available from: http:\/\/www.morphochem.de"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201508330"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.05.018"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2010.11.010"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2012.11.040"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules20046254"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.04.058"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01458-06"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-015-1352-6"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.07.010"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.07.077"},{"key":"e_1_3_4_73_1","unstructured":"Actelion Pharmaceuticals Ltd. Quinolone Derivatives. WO2014178008A1. 2014."},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.08.063"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml100253p"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.01.025"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1021\/ol2026153"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5MD00429B"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.03.080"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml4003138"},{"key":"e_1_3_4_81_1","unstructured":"Yakushiji F Hayashi Y. Antibacterial agents containing hybrid molecule of myxopyronins and holothin and pharmaceutical compositions containing them. JP 2012201669. 2012."},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja000575w"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm400707f"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.13.16"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.12561"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401509e"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.03.010"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.07.064"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00706-014-1364-9"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.04.037"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01715-09"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja503911p"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm400265k"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01525-09"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02474-12"},{"key":"e_1_3_4_96_1","unstructured":"BAL30072 Basilea Pharmaceutica website. 2016. [cited 2016 Feb 24] Available from: http:\/\/www.basilea.com\/Portfolio\/BAL30072"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2016.1187597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:59:48Z","timestamp":1769720388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2016.1187597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,31]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7,2]]}},"alternative-id":["10.1080\/17460441.2016.1187597"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2016.1187597","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}